FinsnoBio and Accelero Biostructures Announce Partnership for X-Ray Crystallography Drug Discovery
San Francisco | July 6, 2021 – In conjunction with the BIO 2021 conference, Snøhamer Group and FinsnoBio proudly announce a new drug discovery partnership with the world’s leading x-ray crystallography enterprise Accelero Biostructures.
FinsnoBio, sister to gene-therapy company NysnoBio, works to leverage small molecules to induce Parkin enzyme activity, improve mitochondrial health, and restore proper function to a wide variety of cells. While the therapeutic potential of Parkin has been well known for years, the lack of effective drug discovery technologies has hindered our ability to make use of this highly validated target—until now.
To this end, FinsnoBio’s new strategic partnership with Accelero Biostructures (ABS) will apply the ABS-OneStep platform to the Parkin pathway, yielding visual intelligence demonstrating the chemistry capable of activating this high-value protein.
Fragment-based drug discovery (FBDD)
X-ray crystallography solution
“Together, FinsnoBio and Accelero Biostructures hold the potential to dramatically accelerate Parkin hit generation, combining decades of scientific expertise with a cutting-edge approach to fragment-based drug discovery.”
– Dr. Jennifer Johnston, FinsnoBio Cofounder and CEO
The science that makes the difference: ABS-OneStep innovations resolve key bottlenecks that have hindered conventional FBDD for decades. By providing high-resolution visual data for drug/target interaction for every hit identified, Accelero’s protein X-ray crystallography method eliminates the guesswork associated with traditional FBDD.
“After testing and validating ABS-OneStep on multiple diverse protein targets, we are now very excited to deploy our platform on Parkin. ABS-OneStep quickly and reliably unlocks vast amounts of experimental data on drug-target interactions with novel chemical matter. Our platforms have already resulted in the founding of one oncology therapeutics company, and we are very excited to now launch this new venture with FinsnoBio.”
– Debanu Das, ABS Cofounder and CEO
FinsnoBio’s Long-Term, AI-Driven Drug Discovery Strategy: This partnership with ABS is just the first of a series of anticipated collaborations built to advance the company’s drug discovery strategies to unleash the power of Parkin and develop powerful new drugs. Adds Johnston, “Discovery tools like ABS-OneStep will allow the FinsnoBio team to apply our decades of experience, emerging from HTS campaigns with not only novel, patentable, developable chemical matter, but a compound interaction map that will power future drug discovery efforts with productive interaction sites on Parkin. With a near atomic-level understanding of how and where the visible hits interact with Parkin, our ability to develop ideas into molecules, and molecules into drugs, is transformational toward delivering on the potential of this highly validated therapeutic target.“
For more information on FinsnoBio, its partnership with Accelero BioStructures, and overall innovations in Parkin therapeutics, contact us at info@finsnobio.com
